RU2769251C2 - Комбинированная терапия для лечения гепатоцеллюлярной карциномы - Google Patents

Комбинированная терапия для лечения гепатоцеллюлярной карциномы Download PDF

Info

Publication number
RU2769251C2
RU2769251C2 RU2019108259A RU2019108259A RU2769251C2 RU 2769251 C2 RU2769251 C2 RU 2769251C2 RU 2019108259 A RU2019108259 A RU 2019108259A RU 2019108259 A RU2019108259 A RU 2019108259A RU 2769251 C2 RU2769251 C2 RU 2769251C2
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
amino
inhibitor
cdk
pyrimidin
Prior art date
Application number
RU2019108259A
Other languages
English (en)
Russian (ru)
Other versions
RU2019108259A3 (OSRAM
RU2019108259A (ru
Inventor
Ананд СЕЛВАРАДЖ
Питер Смит
Original Assignee
Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйсай Ар Энд Ди Менеджмент Ко., Лтд. filed Critical Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Publication of RU2019108259A publication Critical patent/RU2019108259A/ru
Publication of RU2019108259A3 publication Critical patent/RU2019108259A3/ru
Application granted granted Critical
Publication of RU2769251C2 publication Critical patent/RU2769251C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2019108259A 2016-08-23 2017-08-23 Комбинированная терапия для лечения гепатоцеллюлярной карциномы RU2769251C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378455P 2016-08-23 2016-08-23
US62/378,455 2016-08-23
PCT/US2017/048183 WO2018039324A1 (en) 2016-08-23 2017-08-23 Combination therapies for the treatment of hepatocellular carcinoma

Publications (3)

Publication Number Publication Date
RU2019108259A RU2019108259A (ru) 2020-09-25
RU2019108259A3 RU2019108259A3 (OSRAM) 2020-11-24
RU2769251C2 true RU2769251C2 (ru) 2022-03-29

Family

ID=59772765

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019108259A RU2769251C2 (ru) 2016-08-23 2017-08-23 Комбинированная терапия для лечения гепатоцеллюлярной карциномы

Country Status (14)

Country Link
US (1) US20190175598A1 (OSRAM)
EP (1) EP3503923B1 (OSRAM)
JP (1) JP7190425B2 (OSRAM)
KR (1) KR102466192B1 (OSRAM)
CN (1) CN109803684B (OSRAM)
AU (1) AU2017315357B2 (OSRAM)
BR (1) BR112019003722A2 (OSRAM)
CA (1) CA3034875C (OSRAM)
ES (1) ES2966469T3 (OSRAM)
IL (1) IL264950B2 (OSRAM)
MX (1) MX2019002115A (OSRAM)
RU (1) RU2769251C2 (OSRAM)
SG (1) SG11201901472TA (OSRAM)
WO (1) WO2018039324A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019205821C1 (en) 2018-01-08 2025-02-13 Pharmacosmos Holding A/S G1T38 superior dosage regimes
HUE064843T2 (hu) 2018-05-14 2024-04-28 Pfizer Orális oldat kiszerelés
TW202128173A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
JP2023533903A (ja) * 2020-05-15 2023-08-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｆｇｆｒ４阻害剤の経口製剤によるがんの治療方法
JP2025520303A (ja) 2022-05-30 2025-07-03 石▲薬▼集▲團▼中奇制▲薬▼技▲術▼（石家庄）有限公司 癌治療用の医薬組み合わせ物および医薬組成物
WO2025113607A1 (zh) * 2023-11-30 2025-06-05 石药集团中奇制药技术（石家庄）有限公司 联合治疗肿瘤的药物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130232A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
WO2012129344A1 (en) * 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2013006368A1 (en) * 2011-07-01 2013-01-10 Novartis Ag Combination therapy
WO2015057938A1 (en) * 2013-10-18 2015-04-23 Eisai R&D Management Co., Ltd. Pyrimidine fgfr4 inhibitors
WO2016025650A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
DE19959546A1 (de) 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
IL150638A0 (en) 2000-01-18 2003-02-12 Aventis Pharma Inc Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 [4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one
DK1252155T3 (da) 2000-01-18 2005-04-04 Aventis Pharma Inc Ethanolsolvat af (-)-cis-2-(2-chlorphenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-on
AU2001287157A1 (en) 2000-09-12 2002-03-26 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
CN101001857B (zh) 2002-01-22 2011-06-22 沃尼尔·朗伯有限责任公司 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
BRPI0412259B1 (pt) 2003-07-22 2019-08-20 Astex Therapeutics Limited Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica
WO2006077424A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
CA2594477C (en) 2005-01-21 2016-07-12 Astex Therapeutics Limited Pharmaceutical compounds
WO2006077425A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
JP2008255008A (ja) 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ 滑膜細胞増殖抑制剤
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
WO2008001101A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
US20090263398A1 (en) 2006-07-14 2009-10-22 Astex Therapeutics Limited Pharmaceutical combinations
EP2046330A2 (en) 2006-07-14 2009-04-15 Astex Therapeutics Limited Pharmaceutical combinations
US20090318430A1 (en) 2006-07-21 2009-12-24 Astex Therapeutics Limited Medical use of cyclin dependent kinases inhibitors
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
US7902147B2 (en) 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
EP2282995B1 (en) * 2008-05-23 2015-08-26 Novartis AG Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
US8685980B2 (en) 2008-08-22 2014-04-01 Novartis Ag Pyrrolopyrimidine compounds and their uses
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
LT2632467T (lt) 2010-10-25 2016-09-12 G1 Therapeutics, Inc. Cdk inhibitoriai
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
EP2934515B1 (en) 2012-12-20 2018-04-04 Novartis AG A pharmaceutical combination comprising binimetinib
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US9464092B2 (en) 2013-03-15 2016-10-11 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
HRP20211879T1 (hr) * 2013-08-14 2022-03-04 Novartis Ag Kombinirana terapija za liječenje raka
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN104529904B (zh) 2015-01-09 2016-08-31 苏州明锐医药科技有限公司 玻玛西尼的制备方法
US20160220569A1 (en) 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
EP3283465B1 (en) 2015-04-14 2021-01-06 Eisai R&D Management Co., Ltd. Crystalline fgfr4 inhibitor compound and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130232A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
WO2012129344A1 (en) * 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2013006368A1 (en) * 2011-07-01 2013-01-10 Novartis Ag Combination therapy
WO2015057938A1 (en) * 2013-10-18 2015-04-23 Eisai R&D Management Co., Ltd. Pyrimidine fgfr4 inhibitors
WO2016025650A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Jessica A. Sorrentino et al. G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors Molecular and Cellular Biology, Genetics, 107th Annual Meeting 2016; April 16-20, найдено онлайн, найдено в Интернете: https://cancerres.aacrjournals.org/content/76/14_Supplement/2824. *
Jessica A. Sorrentino et al. G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors Molecular and Cellular Biology, Genetics, 107th Annual Meeting 2016; April 16-20, найдено онлайн, найдено в Интернете: https://cancerres.aacrjournals.org/content/76/14_Supplement/2824. Matthew S et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines, Mol Cancer Ther. 2009 Feb;8(2):324-32, найдено онлайн, найдено в Интернете: https://mct.aacrjournals.org/content/8/2/324.long. *
Matthew S et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines, Mol Cancer Ther. 2009 Feb;8(2):324-32, найдено онлайн, найдено в Интернете: https://mct.aacrjournals.org/content/8/2/324.long. *
Yufang Che. Combination of flavopiridol and embelin effectively inhibit cell growth in hepatocellular carcinoma depending on regulatory relationship between CDK6 and XIAP, Medicinal Chemistry Research, 2012, volume 21, pages 3369-337, , найдено ондайн, найдено в Интернете: https://link.springer.com/article/10.1007/s00044-011-9867-y. *
Yufang Che. Combination of flavopiridol and embelin effectively inhibit cell growth in hepatocellular carcinoma depending on regulatory relationship between CDK6 and XIAP, Medicinal Chemistry Research, 2012, volume 21, pages 3369-337, реферат, найдено ондайн, найдено в Интернете: https://link.springer.com/article/10.1007/s00044-011-9867-y. *

Also Published As

Publication number Publication date
SG11201901472TA (en) 2019-03-28
AU2017315357B2 (en) 2022-12-01
CN109803684A (zh) 2019-05-24
ES2966469T3 (es) 2024-04-22
JP2019528302A (ja) 2019-10-10
CN109803684B (zh) 2022-08-23
AU2017315357A1 (en) 2019-02-28
CA3034875C (en) 2024-05-28
EP3503923B1 (en) 2023-10-04
KR102466192B1 (ko) 2022-11-14
RU2019108259A3 (OSRAM) 2020-11-24
WO2018039324A1 (en) 2018-03-01
RU2019108259A (ru) 2020-09-25
MX2019002115A (es) 2019-07-08
JP7190425B2 (ja) 2022-12-15
EP3503923A1 (en) 2019-07-03
IL264950A (en) 2019-05-30
KR20190040996A (ko) 2019-04-19
CA3034875A1 (en) 2018-03-01
US20190175598A1 (en) 2019-06-13
IL264950B2 (en) 2024-01-01
BR112019003722A2 (pt) 2019-05-28
IL264950B1 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
RU2769251C2 (ru) Комбинированная терапия для лечения гепатоцеллюлярной карциномы
JP5159303B2 (ja) 放出制御組成物
US20090042914A1 (en) Delayed release formulations of 6-mercaptopurine
JP7219224B2 (ja) 乳癌の治療のための組合せ療法
JP7665700B2 (ja) 肝細胞癌の治療のための併用療法
KR102573278B1 (ko) 약학적 조성물 및 이의 용도
JP2022160654A (ja) 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
JP7704690B2 (ja) 抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム
US20250057777A1 (en) Intestine-Targeted Drug Delivery Compositions and Preparation Methods Thereof
RU2787993C2 (ru) Комбинированные терапии для лечения гепатоцеллюлярной карциномы